The Importance Of ePRO To Support NASH/NAFLD Unmet Clinical Research And Medical Needs

Metabolic Dysfunction-Associated SteatoHepatitis (MASH), formerly known as NonAlcoholic SteatoHepatitis (NASH), affects around 115 million adults globally and is the most severe form of NonAlcoholic Fatty Liver Disease (NAFLD). NASH/MASH is strongly linked to obesity and diabetes, severely impacting quality of life and often requiring invasive procedures like liver transplants. Alarmingly, even children are affected, with NAFLD being the leading cause of chronic liver disease in American children. Despite the urgency, few treatments are approved, and clinical research remains limited, with a lack of patient-centric evaluations.

This article stresses the importance of including patient-reported outcomes (PROs) in clinical trials to better understand patient experiences and improve treatment approaches. It suggests utilizing electronic PROs (ePROs) and eDiaries to capture symptoms accurately and conveniently, potentially enhancing patient comfort and compliance. Increasing ePROs in NASH trials could provide valuable insights into patient perspectives and aid in developing more effective treatments.